Recently added Catalysts

CGTX Positive Sentiment

Episode 7: Quantitative EEG – Effects of CT1812 on Measures of Synaptic Function in Alzheimer’s Disease

Thursday, November 16, 2023 BiopharmaWatch Research 1 min read

Key Takeaway: The article discusses Episode 7 of a series focusing on CT1812's effects on synaptic function in Alzheimer's disease. Moderated by Dr. Anthony Caggiano, it features insights from prominent researchers including Dr. Willem de Haan and Dr. Philip Scheltens. Key findings from the SEQUEL study are highlighted, emphasizing the potential of EEG in neurodegenerative diseases.

Price reaction · baseline $1 (2023-11-16 close) · hit after-hours · clean, no other CGTX news in the window

day 0 close

+3%

Market Sentiment Analysis

POSITIVE FACTORS

Discussion on innovative treatment CT1812 for Alzheimer's disease.
Insights from leading experts in the field of neurology.
Focus on the SEQUEL study design and its implications.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice

Best trade, last catalyst

+35%

120-day peak, hindsight

Typical move

8.3%

average across 6 past catalysts

Cash runway

~33 mo

Minimal dilution risk

Lead asset

Oxytocin

Phase 2 · Oxidative Stress

Full Press Release Details

Episode 7: Quantitative EEG – Effects of CT1812 on Measures of Synaptic Function in Alzheimer’s Disease

Featuring:

Anthony Caggiano, M.D., Ph.D.

(moderator)

Cognition Therapeutics

Chief Medical Officer

Willem de Haan, M.D., Ph.D.

Alzheimer Center at Amsterdam University Medical Center

Neurologist and Senior Researcher

Philip Scheltens, M.D.

EQT Life Sciences

Partner and Head of Dementia Fund

Former Director of the Alzheimer Center at Amsterdam University Medical Center

Index: